FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321261241> ?p ?o ?g. }

• W4321261241 abstract "Objective: This review aims to bring updates about the relationship between the silicone implant and the breast implantassociated anaplastic large cell lymphoma (BIA-LCL), in order to have a better knowledge about this disease. Despite the low risk of its development, a better understanding of BIA-ALCL is of interest to women, oncologists, breast specialists, plastic surgeons, regulatory agencies, and the general public, as the number of women with breast implants is increasing worldwide. Methods: This article is based on a review of publications on the topic. A search for articles was carried out through the SciELO databases, at the interface of the U.S. National Library of Medicine and National Center for Biotechnology Information (PubMed) and Latin American and Caribbean Literature on Health Sciences (LILACS). Results: BIA-ALCL is a very rare disease (1 case per 1–3 million women with implants), accounting for 2–3% of these lymphomas in adults and 0.5% of breast cancers and occurs between 8 and 10 years after breast cancer and implantation of a breast prosthesis. Textured implants are the most associated because they have a greater contact surface, so more biofilm is formed, causing bacterial adhesion. Most patients have peri-implant effusion and less often have a mass. Other described symptoms included breast enlargement, skin rash, capsular contracture, and lymphadenopathy. Lymphoma may be located in the seroma cavity or may involve pericapsular fibrous tissue. To make the diagnosis, imaging tests and cytological analysis must be performed. The fluid must be aspirated and is usually cloudy and thick, with large pleomorphic epithelioid lymphocytes, abundant cytoplasm, eccentric reniform nucleus and prominent nucleolus, and anaplastic lymphoma (ALK). Morphological and immunophenotypic features are indistinguishable from those of ALK-negative ALCL. Conclusion: The treatment of BIA-LCL includes implant removal, complete capsulectomy, excision of suspected adenopathy, and excision of lymphoma margins. Surgeons may consider removal of the contralateral implant as approximately 4.6% of cases have demonstrated incidental lymphoma in the contralateral breast. There are no data to recommend a mastectomy, sentinel lymph node biopsy, axillary lymphadenectomy, or breast reconstruction. The best prognosis is with complete capsule elimination surgery. Follow-up is done every 3–6 months for 2 years, in addition to imaging tests and the segment will depend on the patient’s clinical manifestations." @default.
• W4321261241 created "2023-02-18" @default.
• W4321261241 creator A5028641667 @default.
• W4321261241 creator A5030460956 @default.
• W4321261241 creator A5034323043 @default.
• W4321261241 creator A5056990654 @default.
• W4321261241 creator A5078009952 @default.
• W4321261241 date "2022-01-01" @default.
• W4321261241 modified "2023-09-27" @default.
• W4321261241 title "BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA: A LITERATURE REVIEW" @default.
• W4321261241 doi "https://doi.org/10.29289/259453942022v32s1012" @default.
• W4321261241 hasPublicationYear "2022" @default.
• W4321261241 type Work @default.
• W4321261241 citedByCount "0" @default.
• W4321261241 crossrefType "proceedings-article" @default.
• W4321261241 hasAuthorship W4321261241A5028641667 @default.
• W4321261241 hasAuthorship W4321261241A5030460956 @default.
• W4321261241 hasAuthorship W4321261241A5034323043 @default.
• W4321261241 hasAuthorship W4321261241A5056990654 @default.
• W4321261241 hasAuthorship W4321261241A5078009952 @default.
• W4321261241 hasBestOaLocation W43212612411 @default.
• W4321261241 hasConcept C121608353 @default.
• W4321261241 hasConcept C126322002 @default.
• W4321261241 hasConcept C141071460 @default.
• W4321261241 hasConcept C142724271 @default.
• W4321261241 hasConcept C2777872185 @default.
• W4321261241 hasConcept C2778187792 @default.
• W4321261241 hasConcept C2778570526 @default.
• W4321261241 hasConcept C2779338263 @default.
• W4321261241 hasConcept C2779409168 @default.
• W4321261241 hasConcept C2781411149 @default.
• W4321261241 hasConcept C530470458 @default.
• W4321261241 hasConcept C71924100 @default.
• W4321261241 hasConcept C81182388 @default.
• W4321261241 hasConceptScore W4321261241C121608353 @default.
• W4321261241 hasConceptScore W4321261241C126322002 @default.
• W4321261241 hasConceptScore W4321261241C141071460 @default.
• W4321261241 hasConceptScore W4321261241C142724271 @default.
• W4321261241 hasConceptScore W4321261241C2777872185 @default.
• W4321261241 hasConceptScore W4321261241C2778187792 @default.
• W4321261241 hasConceptScore W4321261241C2778570526 @default.
• W4321261241 hasConceptScore W4321261241C2779338263 @default.
• W4321261241 hasConceptScore W4321261241C2779409168 @default.
• W4321261241 hasConceptScore W4321261241C2781411149 @default.
• W4321261241 hasConceptScore W4321261241C530470458 @default.
• W4321261241 hasConceptScore W4321261241C71924100 @default.
• W4321261241 hasConceptScore W4321261241C81182388 @default.
• W4321261241 hasLocation W43212612411 @default.
• W4321261241 hasOpenAccess W4321261241 @default.
• W4321261241 hasPrimaryLocation W43212612411 @default.
• W4321261241 hasRelatedWork W2337259244 @default.
• W4321261241 hasRelatedWork W2792570309 @default.
• W4321261241 hasRelatedWork W2796810391 @default.
• W4321261241 hasRelatedWork W2892318591 @default.
• W4321261241 hasRelatedWork W2910488906 @default.
• W4321261241 hasRelatedWork W2991608616 @default.
• W4321261241 hasRelatedWork W3135956047 @default.
• W4321261241 hasRelatedWork W4210912830 @default.
• W4321261241 hasRelatedWork W4226103717 @default.
• W4321261241 hasRelatedWork W4226419711 @default.
• W4321261241 isParatext "false" @default.
• W4321261241 isRetracted "false" @default.
• W4321261241 workType "article" @default.